For glioma phenotyping, IDH1/2, 1p/19q, MGMT, hTERT, TP53, PTEN, EGFR, and ATRX mutations are usually regarded as the key factors influencing postoperative therapeutic decisions, such as radiotherapy, chemotherapy, molecular targeted therapy and immune therapy (37). Here, IDH1 is linked to central nervous system cancer.